GlaxoSmithKline And Genmab Announce Positive Top-line Results In Ofatumumab Chronic Lymphocytic Leukaemia Pivotal Study GlaxoSmithKline (LSE and NYSE: GSK) and Genmab A/S (OMX: GEN) announced today positive top-line results from an interim analysis of the Phase III pivotal study evaluating ofatumumab (HuMax-CD20®) in two difficult to treat groups of patients with chronic lymphocytic leukaemia (CLL). At the interim analysis, the study met the primary endpoint in both populations and the results from the secondary endpoints also support the primary endpoint.
Source: www.medicalnewstoday.comMultaq(R) (dronedarone) Granted FDA Priority Review For Patients With Atrial Fibrillation Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced that U.S. Food and Drug Administration (FDA) has assigned priority review status for its New Drug Application (NDA) for Multaq(R) (dronedarone). The priority review period begins on July 31, 2008.
Source: www.medicalnewstoday.comSingle Pill Combinations Diovan HCT® And Exforge® Approved In US As First-line Treatments For High Blood Pressure The US Food and Drug Administration (FDA) has approved two single-pill combination medications, Diovan HCT® (valsartan and hydrochlorothiazide) and Exforge® (amlodipine and valsartan), as initial or 'first-line' therapies in patients likely to need multiple
drugs to achieve their blood pressure goals. The FDA approval of Diovan HCT and Exforge for first-line use reinforces current US guideline recommendations to start appropriate patients on combination therapy[1].
Source: www.medicalnewstoday.comAbbott Study Shows Investigational Heat-Stable Norvir® Tablet Provides Similar Drug Levels To Current Norvir Capsule Abbott presented pivotal data at the XVII International AIDS Conference (AIDS 2008) in Mexico City showing that its investigational Norvir® (ritonavir) tablet and the current soft-gelatin capsule provide similar levels of drug in the blood. The heat-stable Norvir tablet will not require refrigeration, making it more convenient for patients to use, particularly in developing countries where the majority of people with HIV live.
Source: www.medicalnewstoday.comBRIDION(R) (sugammadex) Injection - First And Only Selective Relaxant Binding Agent - Approved In European Union Schering-Plough Corporation (NYSE: SGP) announced that the European Commission (EC) has approved BRIDION(R) (sugammadex) injection, the first and only selective relaxant binding agent (SRBA) and the first major pharmaceutical advance in the field of anesthesia in two decades.
Source: www.medicalnewstoday.comNew Data Shows HIV Therapy Tipranavir (Aptivus®) Is Effective And Well Tolerated In Children Boehringer Ingelheim presented new 100 week data at the International AIDS Conference demonstrating Aptivus® (tipranavir) long-term efficacy and safety in treatment-experienced children. Results from this two-year study show that Aptivus® enabled the children to achieve sustained virologic and immunologic responses and was a well-tolerated antiretroviral therapy.
Source: www.medicalnewstoday.com
# posted by Network @ 7:00 PM
